Chemodex

Cabozantinib

CHF 150.00
In stock
CDX-C0755-M01010 mgCHF 150.00
CDX-C0755-M05050 mgCHF 474.00
More Information
Product Details
Synonyms BMS-907351; XL184
Product Type Chemical
Properties
Formula C28H24FN3O5
MW 501.5
CAS 849217-68-1
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (20mg/ml). Slightly soluble in ethanol.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key ONIQOQHATWINJY-UHFFFAOYSA-N
Smiles O=C(NC1=CC=C(OC2=C3C=C(C(OC)=CC3=NC=C2)OC)C=C1)C4(C(NC5=CC=C(C=C5)F)=O)CC4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Cabozantinib is a potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of endothelial growth factor receptor 2 (VEGFR2) (IC50=0.035nM), the hepatocyte growth factor receptor c-Met (IC50=1.3nM), AXL (IC50=7nM), fms like tyrosine kinase 3 (FLT3) (IC50=11.3nM), mast/stem cell growth factor (KIT) (IC50=4.6nM), RET (IC50=5.2nM), tyrosine-protein kinase receptor (TIE-2) (IC50=14.3nM) and RON (IC50=124nM). Cabozantinib reduces cell proliferation and vascular density. It also induces apoptosis and intratumoral hypoxia. Cabozantinib exhibits dose-related tumor growth inhibition, tumor regression, angiogenesis and/or metastasis inhibition in a broad range of preclinical tumor models. The anticancer compound cabozantinib has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and glioblastoma.

Product References

(1) Y. Zhang, et al.; IDrugs 13, 112 (2010) | (2) R. Kurzrock, et al.; J. Clin. Oncol. 29, 2660 (2011) | (3) F.M. Yakes, et al.; Mol. Canc. Ther. 10, 2298 (2011) | (4) S. Roy, et al.; Anticancer Agents Med. Chem. 15, 37 (2015) (Review) | (5) N.M. Tannir, et al.; Curr. Oncol. Rep. 19, 14 (2017) (Review) | (6) C. Grullich; Recent Res. Cancer Res. 211, 67 (2018) (Review) | (7) J.N. Markowitz & K.M. Fancher;; Pharmacotherapy 38, 357 (2018) (Review) | (8) A. Desai & E.J. Small; Future Oncol. 15, 2337 (2019) (Review) | (9) J. Trojan; Drugs 80, 1203 (2020) (Review)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.